PPARδ agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-08-23. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Common internet and media name. |
| Research code | GW501516 | Also written GW-1516. |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator. |
| Development status | Discontinued | Clinical development halted after rodent cancer findings. |
| Regulatory status | Prohibited in sport | Listed by WADA; not approved as medicine. |
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Sontra Medical, Inc. (acquired by Echo Therapeutics) fqubed, Inc. (acquired by Nuvo Research) Stratagent LifeSciences (acquired by Corium International) Seventh Sense Biosystems (now Your Bio Health, acquired by Hims and Hers) Dx Biosciences Entrega Liquideon, LLC CAGE Bio Inc. Fount Biosciences inTumo Therapeutics i2o Therapeutics Trillion Bio
=== Protein degradation === Arginine phosphorylation by McsB kinase marks proteins for degradation by a Clp protease. The arginine phosphorylation system, which is widely distributed across Gram-positive bacteria, appears to be functionally analogous to the eukaryotic ubiquitin–proteasome system.
After the conclusion of the visit, Trump posted on Truth Social, where he confirmed the two leaders would meet again at the APEC China 2026 in Shenzhen in November and the 2026 G20 Miami summit in December. He said "Much has been, and will be, accomplished. I look forward to our next meeting!" On September 26, the government of China announced that the leaders of China and the United States reached an eight-point consensus, including:
Early medical texts, especially the Carakasaṃhitā and Suśrutasaṃhitā, are often claimed to contain early references to rasaśāstra. Where these texts use the word rasa, later commentators interpret rasa as mercury, despite the word having various other meanings. The earliest mentions of mercury are to the unprocessed substance and it is not until the 9th century Kalyāṇakāraka that we find recipes for purifying and calcination. The 13th century Śārṅgadharasaṃhitā also contains elaborate descriptions of the processing and uses of mercury. An important feature is the use of metals, including several that are toxic. In addition to mercury, gold, silver, iron, copper, tin, lead, zinc and bell metal are used. In addition to these metals, salts and other substances such as coral, seashells, and feathers are also used. The usual means used to administer these substances is by preparations called bhasma, Sanskrit for "ash". Calcination, which is described in the literature of the art as śodhana, "purification", is the process used to prepare these bhasma for administration. Sublimation and the preparation of a mercury sulfide are also in use in the preparation of its materia medica. A variety of methods are used to achieve this. One involves the heating of thin sheets of metal and then immersing them in oil (taila), extract (takra), cow urine (gomutra) and other substances. Others are calcined in crucibles heated with fires of cow dung (puttam). Ayurvedic practitioners believe that this process of purification removes undesirable qualities and enhances their therapeutic power.
== Timeline of detections == NPI was first identified in the UK in August 2024 by WEDINOS as samples W054816 and W057074, then the full chemical characterisation and first literature reported sample was provided by CanTEST in Australia in September 2024,. NPI was later detected in the Netherlands in May 2025, and in Finland in early 2025.
Sources: en.wikipedia.org
Immune checkpoint inhibitors: drugs that block immune system checkpoints to allow immune cells to respond more strongly to the cancer. T-cell transfer therapy: a treatment that takes T-cells from the tumor and selects or changes them in the lab to better attack cancer cells, then reintroduces them into the patient. Monoclonal antibodies: designed to bind to specific targets on cancer cells, marking cancer cells so that they will be better seen and destroyed by the immune system. Treatment vaccines: also known as therapeutic cancer vaccines, help the immune system learn to recognize and react to mutant proteins specific to the tumor and destroy cancer cells containing them. Immune system modulators: agents that enhance the body's immune response against cancer. Immunotherapies can be categorized as active or passive based on their ability to engage the host immune system against cancer. Active immunotherapy specifically targets tumor cells via the immune system. Examples include therapeutic cancer vaccines (also known as treatment vaccines, which are designed to boost the body's immune system to fight cancer), CAR-T cells, and targeted antibody therapies. In contrast, passive immunotherapy does not directly target tumor cells, but enhances the ability of the immune system to attack cancer cells. Examples include checkpoint inhibitors and cytokines. Active cellular therapies aim to destroy cancer cells by recognition of distinct markers known as antigens. In cancer vaccines, the goal is to generate an immune response to these antigens through a vaccine.
Some methods of creating a trophy mount do not involve preserving the actual body of the animal. Instead, detailed photos and measurements are taken of the animal so a taxidermist can create an exact replica in resin or fiberglass that can be displayed in place of the real animal. No animals are killed in the creation of this type of trophy mount. One situation where this is practiced is in the world of sport fishing where catch and release is becoming increasingly prevalent. Reproduction mounts are commonly created for (among others) trout, bass, and large saltwater species such as the swordfish and blue marlin. Another situation where reproduction trophies are created is when endangered species are involved. Endangered and protected species, such as the rhinoceros, are hunted with rifles loaded with tranquilizer darts rather than real bullets. While the animal is unconscious, the hunter poses for photos with the animal while it is measured for the purpose of creating a replica, or to establish what size of prefabricated fiberglass trophy head can be purchased to most closely approximate the actual animal. The darted animal is not harmed. The hunter then displays the fiberglass head on the wall in lieu of the real animal's head to commemorate the experience of the hunt.
The class of nitazene opioids is defined chemically by the presence of the benzimidazole core structure and pharmacologically by μ opioid agonism. Nitazenes are benzimidazoles that are substituted with a dialkylaminoethyl group at the 1-position, in the 2-position with a substituted benzyl group and often in the 5-position, usually with a nitro group but sometimes with other substitutions. Compounds substituted in the 6-position are less effective, while the 4- or 7-substituted compounds are not analgesically active. Analgesically active nitazenes are also usually substituted in the para-position of the benzyl group, and only rarely in the ortho or meta positions. At the methylene linker, a methyl or an amide group is tolerated stereospecifically by the target receptor, and this carbon can also be replaced by CH2CH2, S, or NCH3 with reduced but in some cases still significant activity. Nitazenes are structurally unrelated to most other opioids, but have structural similarity to benzimidazole derivatives from the orphine group, as well as to viminol and its analogues. The compounds are derived from the historical prototype 1-(β-diethylaminoethyl)-2-benzylbenzimidazole (desnitazene). The replacement of the N,N-dialkylamino unit by pyrrolidinyl or piperidinyl, which is found in nitazepyne and nitazepipne compounds, falls into the spectrum of designer drugs. Substitution of the benzyl for thienylmethyl, pyridylmethyl, α-napthylmethyl or styryl has a potency-reducing effect.
== Chemistry == Adrenaline, also known as 3,4,β-trihydroxy-N-methylphenethylamine, is a substituted phenethylamine and catecholamine. It is the N-methylated analogue of norepinephrine (noradrenaline; 3,4,β-trihydroxyphenethylamine) and the N-methylated and β-hydroxylated analogue of dopamine (3,4-dihydroxyphenethylamine). Its chemical composition is Nonacarbon Tridecahydrogen Nitrogen Trioxygen (C9H13NO3).
Sources: en.wikipedia.org
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.
Preclinical rodent studies reported cancers, including liver and bladder tumors, at tested doses. The human relevance of those findings is uncertain, but development was discontinued. No approved human product resulted.
No. It remains an investigational compound without approved therapeutic labeling. Sports regulators prohibit its use, and health agencies have warned against consuming it.
Legal status varies by country, but cardarine is not approved as a medicine in major jurisdictions. It is often sold as a research chemical, a category that may not be lawful for human use. Buyers should check local laws and product labels carefully.